Though KEAP1/NRF2 dysregulation has been considered as an adaptive response that might particularly affect later stages of oncogenesis, recent data in mouse models of pancreatic and lung cancer, where Nrf2 ablation was associated with reduced cellular proliferation, have suggested an early effect (DeNicola et al., 2011). Here, NFE2L2 is linked to lung cancer.